Literature DB >> 2293738

The effect of nifedipine on skin-flap survival.

F M Emery1, T R Kodey, R A Bomberger, D B McGregor.   

Abstract

Nifedipine, a calcium-channel blocker, is a peripheral vasodilator and has been shown to increase blood flow to skin. The hypothesis that nifedipine would thereby improve skin-flap viability was tested by comparing the extent of necrosis of long pedicle flaps in control and nifedipine-treated rats. Thirty male Sprague-Dawley rats were randomized to receive either 2.5 mg/kg nifedipine in chocolate PO t.i.d. or plain chocolate according to protocols. Serum nifedipine levels were determined by gas chromatography. Dorsal cephalad-based random vascular pedicle flaps (2 X 6 cm) were elevated, sutured to their beds, and photographed for computer-aided surface area determinations. The extent of distal flap necrosis was expressed as a percentage of the total flap area, and differences were studied by one-way analysis of variance. The differences between the mean percentages of necrosis at 1 and 2 weeks for the groups were not statistically significant. We conclude that nifedipine has no effect on the extent of necrosis of the random skin flap in the rat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293738     DOI: 10.1097/00006534-199001000-00011

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  2 in total

1.  Overexpressed HIF-2α in Endothelial Cells Promotes Vascularization and Improves Random Pattern Skin Flap Survival.

Authors:  Atsushi Morimoto; Shuhei Tomita; Masaki Imanishi; Go Shioi; Yoshitaka Kihira; Yuki Izawa-Ishizawa; Mitsuru Takaku; Ichiro Hashimoto; Yasumasa Ikeda; Hideki Nakanishi; Toshiaki Tamaki
Journal:  Plast Reconstr Surg Glob Open       Date:  2014-05-07

2.  Trans-Cinnamaldehyde Increases Random Pattern Flap Survival Through Activation of the Nitric Oxide Pathway.

Authors:  Xiaobin Luo; Bin Zhao; Baoxia Chen; Hongyu Chen; Tao Han; Najeeb Bassam Najeeb Bsoul; Hede Yan
Journal:  Drug Des Devel Ther       Date:  2021-02-18       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.